To evaluate safety and determine the recommended Phase II dose (RP2D). We hypothesize that targeting leukemia stem/progenitor cells (LSCs) with nadunolimab (IL…

Myelodysplastic Syndrome(MDS)Acute Myelogenous Leukemia (AML)

~Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT06548230

Phase 1

Phase 1 Trial of Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies

This phase 1 trial will investigate the safety and effectiveness of Thiotepa, Busulfan, and Fludarabine (TBF) conditioning regimen with post-transplant cycloph…

Acute Lymphocytic Leukemia (ALL)Acute Myeloid Leukemia (AML)Acute Leukemia+2 more

~Estimated

~$10 – $7,500

Sawa Ito, MDNCT07565220